In conclusion, in this study, rezivertinib (BPI-7711) showed promising efficacy and a favorable safety profile for the treatment among the locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation in the first-line setting. Here, EGFR is linked to non-small cell lung carcinoma.